RU2552929C1 - Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний - Google Patents

Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний Download PDF

Info

Publication number
RU2552929C1
RU2552929C1 RU2013150861/15A RU2013150861A RU2552929C1 RU 2552929 C1 RU2552929 C1 RU 2552929C1 RU 2013150861/15 A RU2013150861/15 A RU 2013150861/15A RU 2013150861 A RU2013150861 A RU 2013150861A RU 2552929 C1 RU2552929 C1 RU 2552929C1
Authority
RU
Russia
Prior art keywords
eosinophilic
general formula
pharmaceutically acceptable
syndrome
alkyl
Prior art date
Application number
RU2013150861/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2013150861A (ru
Inventor
Владимир Евгеньевич Небольсин
Татьяна Александровна Кромова
Анастасия Владимировна Рыдловская
Александр Григорьевич Чучалин
Original Assignee
Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2013150861/15A priority Critical patent/RU2552929C1/ru
Application filed by Общество С Ограниченной Ответственностью "Фарминтерпрайсез" filed Critical Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority to CA2930231A priority patent/CA2930231C/en
Priority to KR1020167013675A priority patent/KR102312294B1/ko
Priority to LTEP14861410.0T priority patent/LT3069720T/lt
Priority to US15/036,603 priority patent/US9949962B2/en
Priority to DK14861410T priority patent/DK3069720T3/da
Priority to SG10201900504XA priority patent/SG10201900504XA/en
Priority to EA201690798A priority patent/EA030961B1/ru
Priority to PL14861410T priority patent/PL3069720T3/pl
Priority to JP2016530898A priority patent/JP2016540749A/ja
Priority to MX2019006881A priority patent/MX386887B/es
Priority to BR112016010515-0A priority patent/BR112016010515B1/pt
Priority to KR1020207013125A priority patent/KR102312013B1/ko
Priority to ES18206980T priority patent/ES2836887T3/es
Priority to EP14861410.0A priority patent/EP3069720B1/en
Priority to SI201431407T priority patent/SI3069720T1/sl
Priority to ES14861410T priority patent/ES2759530T3/es
Priority to CN201480062492.5A priority patent/CN105722511B/zh
Priority to EA201990529A priority patent/EA037447B1/ru
Priority to EP18206980.7A priority patent/EP3466425B1/en
Priority to HUE14861410A priority patent/HUE046671T2/hu
Priority to EA201891262A priority patent/EA032955B3/ru
Priority to CN201910373584.XA priority patent/CN110200968A/zh
Priority to PL18206980T priority patent/PL3466425T3/pl
Priority to PCT/RU2014/000855 priority patent/WO2015072893A1/ru
Priority to PT148614100T priority patent/PT3069720T/pt
Priority to AU2014349246A priority patent/AU2014349246C1/en
Priority to EA201891261A priority patent/EA032940B1/ru
Priority to MX2016006330A priority patent/MX365781B/es
Priority to UAA201606370A priority patent/UA118687C2/uk
Publication of RU2013150861A publication Critical patent/RU2013150861A/ru
Application granted granted Critical
Publication of RU2552929C1 publication Critical patent/RU2552929C1/ru
Priority to IL245429A priority patent/IL245429B/en
Priority to US15/844,703 priority patent/US10220029B2/en
Priority to JP2018203599A priority patent/JP6589251B2/ja
Priority to AU2018264084A priority patent/AU2018264084C1/en
Priority to JP2019151258A priority patent/JP2020002152A/ja
Priority to JP2019151253A priority patent/JP6758677B2/ja
Priority to CY20191101215T priority patent/CY1122500T1/el
Priority to IL271352A priority patent/IL271352B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2013150861/15A 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний RU2552929C1 (ru)

Priority Applications (38)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
EP18206980.7A EP3466425B1 (en) 2013-11-14 2014-11-12 Use of glutarimide derivatives in the treatment of eosinophilic diseases
LTEP14861410.0T LT3069720T (lt) 2013-11-14 2014-11-12 Farmacinė kompozicija, kurios sudėtyje yra glutarimido dariniai, ir jų panaudojimas eozinofilinių ligų gydymui
US15/036,603 US9949962B2 (en) 2013-11-14 2014-11-12 Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
DK14861410T DK3069720T3 (da) 2013-11-14 2014-11-12 Farmakologisk sammensætning indeholdende glutarimid-derivater og anvendelse deraf til behandling af eosinofile sygdomme
SG10201900504XA SG10201900504XA (en) 2013-11-14 2014-11-12 Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
EA201690798A EA030961B1 (ru) 2013-11-14 2014-11-12 Применение производных глутаримидов для лечения эозинофильных заболеваний
PL14861410T PL3069720T3 (pl) 2013-11-14 2014-11-12 Kompozycja farmaceutyczna zawierająca pochodne glutarimidu i jej zastosowanie w leczeniu chorób eozynofilowych
JP2016530898A JP2016540749A (ja) 2013-11-14 2014-11-12 グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用
MX2019006881A MX386887B (es) 2013-11-14 2014-11-12 Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas
BR112016010515-0A BR112016010515B1 (pt) 2013-11-14 2014-11-12 Uso de um composto derivado de glutarimida no tratamento de doenças eosinofílicas
KR1020207013125A KR102312013B1 (ko) 2013-11-14 2014-11-12 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도
ES18206980T ES2836887T3 (es) 2013-11-14 2014-11-12 Uso de derivados de glutarimida en el tratamiento de enfermedades eosinofílicas
EP14861410.0A EP3069720B1 (en) 2013-11-14 2014-11-12 Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
KR1020167013675A KR102312294B1 (ko) 2013-11-14 2014-11-12 글루타르이미드 유도체를 포함하는 약학적 조성물 및 호산구성 질병 치료에 있어서의 그 용도
ES14861410T ES2759530T3 (es) 2013-11-14 2014-11-12 Composición farmacéutica que contiene derivados de glutarimida, y la aplicación de la misma para el tratamiento de enfermedades eosinofílicas
CN201480062492.5A CN105722511B (zh) 2013-11-14 2014-11-12 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途
EA201990529A EA037447B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний
CA2930231A CA2930231C (en) 2013-11-14 2014-11-12 Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
SI201431407T SI3069720T1 (sl) 2013-11-14 2014-11-12 Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni
AU2014349246A AU2014349246C1 (en) 2013-11-14 2014-11-12 Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
CN201910373584.XA CN110200968A (zh) 2013-11-14 2014-11-12 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途
PL18206980T PL3466425T3 (pl) 2013-11-14 2014-11-12 Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
PCT/RU2014/000855 WO2015072893A1 (ru) 2013-11-14 2014-11-12 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
PT148614100T PT3069720T (pt) 2013-11-14 2014-11-12 Composição farmacológica que contém derivados de glutarimida, e a aplicação da mesma no tratamento de doenças eosinofílicas
EA201891262A EA032955B3 (ru) 2013-11-14 2014-11-12 Применение производного глутаримида для лечения эозинофильных заболеваний
EA201891261A EA032940B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов
MX2016006330A MX365781B (es) 2013-11-14 2014-11-12 Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas.
HUE14861410A HUE046671T2 (hu) 2013-11-14 2014-11-12 Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében
UAA201606370A UA118687C2 (uk) 2013-11-14 2014-12-11 Фармацевтична композиція, яка містить похідні глутарімідів, і їх застосування для лікування еозинофільних захворювань
IL245429A IL245429B (en) 2013-11-14 2016-05-01 A pharmaceutical preparation containing a derivative of glutarimide and its use in the treatment of eosinophilic diseases
US15/844,703 US10220029B2 (en) 2013-11-14 2017-12-18 Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
JP2018203599A JP6589251B2 (ja) 2013-11-14 2018-10-30 グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用
AU2018264084A AU2018264084C1 (en) 2013-11-14 2018-11-15 Pharmaceutical composition comprising glutarimide derivatives, and application thereof for treating eosinophilic diseases
JP2019151258A JP2020002152A (ja) 2013-11-14 2019-08-21 グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用
JP2019151253A JP6758677B2 (ja) 2013-11-14 2019-08-21 グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用
CY20191101215T CY1122500T1 (el) 2013-11-14 2019-11-19 Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων
IL271352A IL271352B (en) 2013-11-14 2019-12-11 A pharmaceutical preparation containing a derivative of glutarimide and its use in the treatment of eosinophilic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Publications (2)

Publication Number Publication Date
RU2013150861A RU2013150861A (ru) 2015-05-20
RU2552929C1 true RU2552929C1 (ru) 2015-06-10

Family

ID=53057723

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Country Status (23)

Country Link
US (2) US9949962B2 (enExample)
EP (2) EP3466425B1 (enExample)
JP (4) JP2016540749A (enExample)
KR (2) KR102312294B1 (enExample)
CN (2) CN105722511B (enExample)
AU (2) AU2014349246C1 (enExample)
BR (1) BR112016010515B1 (enExample)
CA (1) CA2930231C (enExample)
CY (1) CY1122500T1 (enExample)
DK (1) DK3069720T3 (enExample)
EA (4) EA032955B3 (enExample)
ES (2) ES2759530T3 (enExample)
HU (1) HUE046671T2 (enExample)
IL (2) IL245429B (enExample)
LT (1) LT3069720T (enExample)
MX (2) MX365781B (enExample)
PL (2) PL3466425T3 (enExample)
PT (1) PT3069720T (enExample)
RU (1) RU2552929C1 (enExample)
SG (1) SG10201900504XA (enExample)
SI (1) SI3069720T1 (enExample)
UA (1) UA118687C2 (enExample)
WO (1) WO2015072893A1 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019050429A1 (ru) * 2017-09-07 2019-03-14 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
RU2776651C2 (ru) * 2017-08-04 2022-07-22 Ридженерон Фармасьютикалз, Инк. Способы лечения активного эозинофильного эзофагита
US11421036B2 (en) 2013-07-11 2022-08-23 Regeneron Pharmaceuticals, Inc. Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
US11603408B2 (en) 2014-02-28 2023-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
US11964016B2 (en) 2019-03-21 2024-04-23 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
US12090201B2 (en) 2019-08-05 2024-09-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody
US12162943B2 (en) 2006-10-02 2024-12-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909057C (en) * 2013-04-12 2022-03-22 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
CN115427067A (zh) * 2020-04-07 2022-12-02 霍夫赛思生物保健有限公司 使用鲑鱼油组合物的呼吸治疗
CN115803026A (zh) * 2020-06-26 2023-03-14 瓦伦塔有限责任公司 戊二酰亚胺衍生物用于治疗与异常白介素-6活性相关的疾病的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196767A (ja) * 1988-10-11 1990-08-03 Kyowa Hakko Kogyo Co Ltd ヒドロキサム酸誘導体
JPH06504279A (ja) * 1990-12-24 1994-05-19 メレルダウファーマス−ティカルズ　インコーポレイテッド 欝病及び躁病の治療におけるある種のグルタルイミド誘導体の用途
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
PL369863A1 (en) 2001-11-07 2005-05-02 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
DK3072525T3 (en) 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
CA2909057C (en) * 2013-04-12 2022-03-22 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ХАРКЕВИЧ Д.А. Фармакология - М: Медицина, 1996, стр.41-42 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162943B2 (en) 2006-10-02 2024-12-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US12502429B2 (en) 2013-07-10 2025-12-23 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist
US12291571B2 (en) 2013-07-11 2025-05-06 Regeneron Pharmaceuticals, Inc. Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody
US11421036B2 (en) 2013-07-11 2022-08-23 Regeneron Pharmaceuticals, Inc. Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)
US11603408B2 (en) 2014-02-28 2023-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
RU2776651C2 (ru) * 2017-08-04 2022-07-22 Ридженерон Фармасьютикалз, Инк. Способы лечения активного эозинофильного эзофагита
WO2019050429A1 (ru) * 2017-09-07 2019-03-14 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
US11439631B2 (en) 2017-09-07 2022-09-13 “ChemImmune Therapeutics” Limited Liability Company Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
EA039391B1 (ru) * 2017-09-07 2022-01-21 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
US11964016B2 (en) 2019-03-21 2024-04-23 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
US12090201B2 (en) 2019-08-05 2024-09-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей
RU2823588C2 (ru) * 2021-12-15 2024-07-24 Владимир Евгеньевич Небольсин Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний дыхательных путей

Also Published As

Publication number Publication date
PT3069720T (pt) 2019-12-02
AU2014349246A1 (en) 2016-05-19
EA201690798A1 (ru) 2016-08-31
EA037447B1 (ru) 2021-03-30
PL3069720T3 (pl) 2020-05-18
IL245429A0 (en) 2016-06-30
AU2018264084B2 (en) 2020-05-14
JP6758677B2 (ja) 2020-09-23
SI3069720T1 (sl) 2020-02-28
JP6589251B2 (ja) 2019-10-16
US20180104230A1 (en) 2018-04-19
IL245429B (en) 2020-02-27
EA032955B3 (ru) 2020-02-27
MX386887B (es) 2025-03-19
MX2016006330A (es) 2016-09-06
CN110200968A (zh) 2019-09-06
IL271352B (en) 2021-04-29
JP2016540749A (ja) 2016-12-28
KR102312294B1 (ko) 2021-10-15
EP3466425A1 (en) 2019-04-10
KR20200053639A (ko) 2020-05-18
HUE046671T2 (hu) 2020-03-30
UA118687C2 (uk) 2019-02-25
EA201891261A1 (ru) 2018-10-31
CA2930231A1 (en) 2015-05-21
WO2015072893A1 (ru) 2015-05-21
ES2836887T3 (es) 2021-06-28
EA032955B1 (ru) 2019-08-30
JP2019055953A (ja) 2019-04-11
RU2013150861A (ru) 2015-05-20
PL3466425T3 (pl) 2021-04-06
AU2014349246C1 (en) 2019-02-21
EP3069720A8 (en) 2017-10-04
ES2759530T3 (es) 2020-05-11
US20160279114A1 (en) 2016-09-29
IL271352A (en) 2020-01-30
EP3069720A4 (en) 2017-06-21
EA201990529A1 (ru) 2019-07-31
AU2018264084C1 (en) 2020-08-27
BR112016010515B1 (pt) 2022-09-27
CA2930231C (en) 2022-06-14
BR112016010515A2 (enExample) 2017-08-08
CY1122500T1 (el) 2021-01-27
EA032940B1 (ru) 2019-08-30
JP2019214606A (ja) 2019-12-19
MX2019006881A (es) 2019-08-01
CN105722511B (zh) 2019-09-17
CN105722511A (zh) 2016-06-29
KR20160078400A (ko) 2016-07-04
SG10201900504XA (en) 2019-02-27
EP3069720A1 (en) 2016-09-21
JP2020002152A (ja) 2020-01-09
MX365781B (es) 2019-06-13
EA201891262A1 (ru) 2018-10-31
KR102312013B1 (ko) 2021-10-15
AU2014349246A9 (en) 2018-09-20
EP3466425B1 (en) 2020-10-07
EA030961B1 (ru) 2018-10-31
US10220029B2 (en) 2019-03-05
US9949962B2 (en) 2018-04-24
AU2014349246B2 (en) 2018-10-18
LT3069720T (lt) 2020-01-10
DK3069720T3 (da) 2019-11-25
EP3069720B1 (en) 2019-10-30
AU2018264084A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
RU2552929C1 (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
KR102254315B1 (ko) 글루타르이미드 유도체, 이의 용도, 이를 기반으로 한 약학 조성물 및 글루타르이미드 유도체를 생산하는 방법
US20210205348A1 (en) Methods for the Treatment of Bladder Cancer
WO2022132623A1 (en) Small molecules as larp1 ligands
HK40007097A (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
HK40007097B (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
CN108484635B (zh) 4H-噻吩并[2,3-b]噻喃-4-酮类化合物及其应用
HK1224930A1 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
HK1224930B (zh) 包含戊二酰亚胺衍生物的药物组合物及其用於治疗嗜酸细胞性疾病的用途
TWI603965B (zh) 苯并哌喃衍生物或其鹽類用以製造基於巨噬細胞遷移抑制因子之抑制作用的疾病治療劑之用途
CN109134433A (zh) 一种抑制rock的化合物及其应用
CN119954867A (zh) 一种含As（III）化合物及其制备方法与应用

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
QB4A Licence on use of patent

Free format text: LICENCE FORMERLY AGREED ON 20200831

Effective date: 20200831

QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20190115

Effective date: 20200914

PC41 Official registration of the transfer of exclusive right

Effective date: 20201103